SCHEMBL3374335

SCHEMBL3374335

CS(=O)(=O)Nc1ccc(-c2ccc(Oc3ccccc3)cc2)cc1OC(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.51
PTGS1 P23219 2/20 0.49
PTGS2 P35354 2/20 0.49
CYP19A1 P11511 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
MLNR O43193 1/20 0.49
LMNA P02545 1/20 0.49
MMP1 P03956 1/20 0.49
MPO P05164 1/20 0.49
CYP1A2 P05177 1/20 0.49
GLA P06280 1/20 0.49
CYP3A4 P08684 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
TBXA2R P21731 1/20 0.49
SLC6A2 P23975 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379317 0.89 KIF11 (0.65) KIF11PTGS2LMNAHPGDHSD17B10
SCHEMBL3375684 0.86 ACLY (0.43) KIF11PTGS1PTGS2PGRPTGES2
SCHEMBL3376638 0.85 PTGES2 (0.50) KIF11PGRPTGES2NR3C1ABL1
SCHEMBL3376561 0.82 KIF11 (0.61) KIF11CYP3A4PGR
SCHEMBL3377340 0.79 PGR (0.56) KIF11PTGS1PTGS2CYP19A1KDM4E
SCHEMBL3379363 0.79 KIF11 (0.52) KIF11KDM4ECYP3A4MAPTPGR
SCHEMBL3375889 0.78 PGR (0.55) KIF11PTGS1PTGS2CYP19A1KDM4E
SCHEMBL3375802 0.77 KIF11 (0.43) KIF11PTGS1PTGS2LMNAHPGD
SCHEMBL3377563 0.76 CYP2C9 (0.58) PTGS1PTGS2CYP19A1KDM4EMEN1
SCHEMBL13011374 0.75 KIF11 (0.47) KIF11PTGS1PTGS2KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885PTGS1 350/4885PTGS2 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.